Lymphoma
Pipeline by Development Stage
Drug Modality Breakdown
Lymphoma is a ~$75M Part D market (indication-attributable spend) with mature, established therapies dominating but limited newer agent penetration.
Key Trends
- Growth factor support agents (filgrastim biosimilars) command 76% of tracked spending, signaling commodity-level competition
- CD20-directed antibodies (rituximab biosimilars) represent 22% share, reflecting standard-of-care intensity in B-cell lymphomas
- 2,811 active trials indicate sustained pipeline activity, but most are early-phase (Phase 1–2 represent 55% of trial volume)
Career Verdict
Lymphoma is a stable, mature oncology niche with strong employer demand (8,142 jobs) but limited upside growth; best for those seeking established roles in commercial, medical affairs, or clinical operations rather than high-risk innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ZARXIO (filgrastim-sndz) | Novartis | $47M | 63% | Peak | Stable | |
| 2 | RUXIENCE (rituximab-PVVR) | Pfizer | $17M | 23% | Peak | Stable | |
| 3 | NEUPOGEN (filgrastim) | Amgen | $10M | 13% | LOE_APPROACHING | Declining |
Drug Class Breakdown
commoditizing, biosimilar-driven
stable, standard-of-care
declining, legacy therapies
Career Outlook
StableLymphoma is a mature, well-established oncology segment with predictable demand from major pharma. Limited blockbuster upside (market is ~$75M attribution, not billions) but strong stability due to chronic disease prevalence and continuous clinical need. Hiring is concentrated in commercial, medical affairs, and clinical operations—ideal for professionals seeking established careers rather than high-risk startup environments.
Breaking In
Enter via commercial or clinical-operations graduate programs at top-tier oncology companies (J&J, AbbVie, Takeda); emphasize teamwork, payer management, and ability to operate in mature, protocol-driven environments.
For Experienced Professionals
If you have 5+ years in oncology or biosimilars, move into medical-affairs leadership or regional reimbursement roles to command $300K+ salaries; avoid pure R&D unless pursuing immuno-oncology or CAR-T engineering, where innovation risk is higher but long-term upside exists.
In-Demand Skills
Best For
Hiring Landscape
Lymphoma specialists are hired primarily by large, diversified oncology companies (Johnson & Johnson, AbbVie, Takeda, AstraZeneca) with 1,373–1,048 open roles across all functions. Commercial roles (1,364 positions, $255K avg.) and medical affairs (264 roles, $302K avg.) are the dominant pathways. Manufacturing and engineering roles are also present, reflecting the complexity of large-molecule production and supply-chain infrastructure required for modern lymphoma therapeutics.
Top Hiring Companies
By Department
Hiring is robust and diversified; commercial and medical-affairs roles command premium salaries ($255K–$307K), making lymphoma a safe destination for mid-to-senior commercial professionals seeking stable employment.
On Market (2)
Approved therapies currently available
Competitive Landscape
72 companies ranked by most advanced pipeline stage
+42 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 12,572 patients across 50 trials
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Study of Rituximab to Treat Chronic Renal Transplant Rejection
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Phase III Copanlisib in Rituximab-refractory iNHL
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Eltrombopag for Peripheral Blood Stem Cell Harvest
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Pembrolizumab in Neoplasms or Lymphomas
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
A Study of the HSP90 Inhibitor AUY922
Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Related Jobs in Oncology
Associate Director, US Medical Learning - Multiple Myeloma/Lymphoma/Myeloid
【今市】プロダクションエンジニア / 設備保全エンジニア
Técnico/a de ingeniería de producción
Sr. Director, Market Access Strategic Marketing
Director, Market Access Strategic Marketing
Manager, Clinical Science
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.